Clinical Trial

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

Study acronym: PANCREAS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated December 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-06-29; most recent amendment 2024-10-08.
Status change: Not Yet Recruiting → Recruiting 2021-09-01
Trial Details
NCT Number NCT04452461
Lead Sponsor Hamilton Health Sciences Corporation
Conditions Pancreatic Adenocarcinoma
Enrollment 30 participants
Start Date 2021-03-01
Primary Completion 2025-12-12 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-10